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Abstract 
 
One size fits all approaches to medicine have become a thing of the past as the understanding of 
individual differences grows. The paper introduces a test for the presence of heterogeneity in treatment 
effects in a clinical trial. .Heterogeneity is assessed on the basis of the predicted individual treatment 
effects (PITE) framework and a permutation test is utilized to establish if significant heterogeneity is 
present. We first use the novel test to show that heterogeneity in the effects of interventions exists in the 
Amyotrophic Lateral Sclerosis Clinical Trials. We then show, using two different predictive models 
(linear regression model and Random Forests) that the test has adequate type I error control. Next, we use 
the ALS data as the basis for simulations to demonstrate the ability of the permutation test to find 
heterogeneity in treatment effects as a function of both effect size and sample size. We find that the 
proposed test has good power to detected heterogeneity in treatment effects when the heterogeneity was 
due primarily to a single predictor, or when it was spread across the predictors. The predictive model, on 
the other hand is of secondary importance to detect heterogeneity. The non-parametric property of the 
permutation test can be applied with any predictive method and requires no additional assumptions to 
obtain PITEs. 
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1. Introduction 
The key premise of precision medicine is the identification and targeting of individuals most likely to 
benefit from a given intervention,1 with the goal of improving  health care outcomes and decreasing 
costs.1,2 Much recent research has focused on statistical approaches for identifying a small number of 
subgroups of individuals who differ in their response to interventions,3–13 while a smaller body of research 
has focused on predicting intervention responses at an individual level.4,14–19 For situations in which 
treatment response is related to a set of covariates which is not small number of clearly defined 
subgroups, individual-level predictions are particularly appropriate. Even if most covariates were 
categorical, with high dimensional data and finite samples individual level predictions may contain more 
information about heterogeneity in treatment effects than is contained in subgroups. This study focuses on 
the use of predicted individual treatment effects (PITE),20,21  a framework based on potential outcomes22,23 
that results in predictions of responses interventions tailored to each individual patient.  
The PITE approach utilizes data from a randomized clinical trial with a potentially very large 
number of baseline covariates to generate predictions from a model or algorithm, which are then used in 
estimating PITEs. The same model or algorithm can then be used to generate treatment effect estimates 
for new subjects not used in training. Given that predictive algorithms have been trained, the next 
question becomes whether the data reveal more variability in individual predictions than would be 
expected due to chance. In other words, ‘Do individuals differ in the effects of the intervention?’ is a 
question that should be answered before PITE estimates from a given trial are used because otherwise the 
PITE predictions provide no information beyond the average treatment effect. This paper proposes a 
permutation test to answer this question using predictions from the PITE framework. The null hypothesis 
of the permutation test is that the PITE predictions explain no more variance than using average treatment 
effect (ATE). An advantage of the proposed method is that it can be generally applied to any method for 
estimating predictions for the treated group and the control group. While methods exist for estimating the 
significance of heterogeneity in treatment effects using kernel regression and instrumental variable 
regression,24,25 the proposed permutation test provides flexibility in choosing the estimator and can use 
machine learning for the two potential outcomes while retaining frequentist properties. The next section 
describes the PITE approach in general terms before providing details of our proposed permutation test. 
In Section 3, we use the PITE framework and the proposed test to evaluate heterogeneity in the effects of 
interventions for ALS; Section 4 uses this test on simulated data to show the type I error rates of the PITE 
permutation test using two different predictive models with and without main effects of covariates. In 
Section 5, we use it as the basis for simulations that demonstrate the ability of the permutation test to find 
heterogeneity in treatment effects as a function of both effect size and sample size. Section 6 concludes 
with a discussion of results. 
2. Permutation test for PITE 
In a clinical trial, we observe the outcome for a given patient under either the experimental or the control 
condition.  This has been highlighted in the causal inference literature23,26,27 and leads to challenges when 
one aims to estimate patient-level treatment effects. The ATE is usually defined as  
ATE = E(Y1) – E(Y0)         (1) 
where E(Y1) is the expected response under experimental treatment and E(Y0 ) the expected response 
under control, possibly also adjusting for covariates. Heterogeneity in treatment effects implies that there 
is individual variability in the ATE such that some individuals are expected to do better than average, and 
some are expected to do worse. It should be noted that when the ATE equals zero it is still possible that 
there are some individuals who would be expected to do better given the treatment than control and others 
who would be expected to do better under control. Therefore, in this paper, we exclude the expected value 
of the PITE from the test, as this value is equal to the ATE and not evidence of individual differences.  
Lamont et al.20 defines PITE as the difference between the potential (or counterfactual predicted) outcome 
under treatment (t) and control (c) for each patient i given their observed covariates 𝑿.   
 PITEi  = 𝑌𝑖
𝑡 – 𝑌𝑖
𝑐         (2) 
where 𝑌𝑖
𝑡 indicates each patient’s potential outcome if they all get the treatment, and 𝑌𝑖
𝑐 is patient’s 
potential outcome if they all in the control condition. Then the difference between ATE in Equation (1) 
and PITE framework in Equation (2) is that PITE focuses on individual’s potential outcome therefore, it 
can be used with any predictive model that allows outcome prediction on a patient level (e.g., random 
forests,28 Bayesian additive regression trees,29 neural networks30). In addition, PITE can be used for 
predictions of treatment effects given information on covariates for patients who are not originally part of 
the clinical trial.  
 While the PITEs from Equation (2) include both the ATE and predicted individual differences in 
the treatment effects, the presence of individual differences has major implications for how a treatment 
would be implemented: if there are individual differences in the treatment effect it suggests that it may be 
worthwhile to collect and use individual level data to help guide treatment decisions. Therefore, we 
propose a permutation test to evaluate whether the individual differences observed in PITEs account for 
significantly more variability than the ATE alone. This paper demonstrates the use of a permutation test 
with two different predictive approaches, Random Forests28 and linear regression. Since 𝑌𝑖
𝑡  and 𝑌𝑖
𝑐 in 
Equation (2) is not observable for any patient under both counterfactual conditions, in this framework, we 
estimate a predicted 𝑌𝑖
∗ as a function of observed baseline covariates: the predicted 𝑌𝑖
𝑡 is estimated by 
𝑓(𝑌?̂?|𝑿𝑖 , 𝑇 = 1) and 𝑌𝑖
𝑐 by 𝑓(𝑌?̂?|𝑿𝑖 , 𝑇 = 0),  where 𝑓(. ) indicates any predictive function. 
Let yjc denote the observed outcome for patient j in the control group while ykt  is the observed 
outcome for patient k in the experimental group. Using linear regression as an example, the outcomes for 
patients in the control group are regressed on their individual characteristics, Xc, via 
 yic = Xcβc + εc          (3) 
which can then be used to obtain individual-level predictions of potential outcomes under control 𝑌𝑖
𝑐. Xc 
is the design matrix, which captures all baseline covariates of the individuals in the control group. The 
error terms, denoted εc, are assumed to be independent and normally distributed.  
Potential outcomes under the experimental condition can be estimated in the same way. 
Individual-level PITE estimates, both for patients in the original trial and those who did not take part in it, 
can then be obtained using Equation 2. It should also be noted that the algorithm or model used will 
determine both the assumptions made and the efficiency of the predictions (e.g., linear models assume 
linearity in the parameters and that all multiway interactions are included in the covariates and tends to 
have increased efficiency when those assumptions are met). This paper proceeds to use both Random 
Forests and the linear model to obtain predictions. We expect that the best model will be situation 
dependent. 
The approach described above will yield a prediction of an individual patient’s treatment effect. 
However, it does not provide a direct test of whether the heterogeneity across individuals observed in the 
PITEs is greater than chance. We therefore propose that a permutation test23,31–34 be used  to assess 
whether the observed differences in individual patients’ PITEs are more variable than what would be 
expected through random chance alone. Our test focuses on the standard deviation (SD) of the PITEs, 
because this estimate quantifies individual differences in the predicted treatment effects. More 
specifically, we test the hypothesis: 
 H0: 𝜎𝑃𝐼𝑇𝐸  = 𝜎𝑐ℎ𝑎𝑛𝑐𝑒   versus  HA: 𝜎𝑃𝐼𝑇𝐸  > 𝜎𝑐ℎ𝑎𝑛𝑐𝑒  
where  𝜎𝑃𝐼𝑇𝐸  is the SD of the PITEs and 𝜎𝑐ℎ𝑎𝑛𝑐𝑒 is the SD of the distribution one would get under zero 
treatment effect heterogeneity. In other words, it is also the variation that would be observed if the 
observed individual differences in the treatment effect are only due to random chance. To test this 
hypothesis, the permutation test first approximates the sampling distribution of PITE’s SD under the null 
hypothesis, i.e. when the set of covariates in the PITE prediction models have no different effect on the 
outcome dependent on treatment (they may be prognostic, but not predictive), and subsequently compares 
the observed SD from the data against the resulting distribution.  
The following algorithm describes the procedure in more detail. 
1) Estimate PITE models and compute 𝑃𝐼𝑇?̂?𝑖,  for all 𝑛 individuals in the dataset using a prediction 
method  
2) Estimate the standard deviation of the estimated PITEs as 
?̂?𝑃𝐼𝑇𝐸 =
1
𝑛 − 1
∑(𝑃𝐼𝑇𝐸𝑖̂ − 𝑃𝐼𝑇𝐸𝑖̂ )
2
𝑛
𝑖=1
 
 where 𝑃𝐼𝑇𝐸𝑖̂ =
1
𝑛
∑ 𝑃𝐼𝑇𝐸𝑖̂
𝑛
𝑖=1 . 
3) Randomly permute the treatment assignment of all patients in the study. 
4) Estimate the PITE model and compute 𝑃𝐼𝑇?̂?𝑖
𝑝
, using the permuted data and the same prediction 
method as used in step 1. 
5) Estimate the standard deviation, ?̂?𝑃𝐼𝑇𝐸
𝑃   of 𝑃𝐼𝑇?̂?𝑖
𝑝
 , in the same manner as in step 2. 
6) Repeat steps 3 through 5, P times.   
7) Obtain the p-value, pP, associated with the above hypothesis as 𝑝𝑃 =
∑ 𝐼(?̂?𝑃𝐼𝑇𝐸
𝑃 >?̂?𝑃𝐼𝑇𝐸)
𝑃
𝑝=1
𝑃
,  with I(.) 
being an indicator function equal to 1  if the condition in the parenthesis is satisfied, and 0 
otherwise.  
8) Reject the above hypothesis at level α if pP < α. 
The above test examines the presence of individual patient heterogeneity on the basis of the original study 
data only. To confirm that heterogeneity also exists in the whole population  for which PITE is used to 
make treatment decisions (as distinct from the study population), one can use a similar procedure as the 
one detailed above, except that ?̂?𝑃𝐼𝑇𝐸  is estimated based on predictions from patients who were not 
enrolled in the original study. 
For each of 1,000 replications in this study, 1,000 permutations were used in our subsequent evaluations. 
Following binomial arguments, this yields a .007% uncertainty in estimated p-values of which the true 
value should be 5%.    
3. Demonstration of the permutation test: An intervention for individuals with ALS 
 
Amyotrophic Lateral Sclerosis (ALS, also known as Motor Neuron Disease) is a neurodegenerative 
disorder that affects motor neurons in the brain and spinal cord. We first estimated the PITE of patients in 
the Pooled Resource Open-access ALS Clinical Trials database (Pro-ACT; 
http://nctu.partners.org/ProACT). In 2011, Prize4Life, in collaboration with the Northeast ALS 
Consortium, and with funding from the ALS Therapy Alliance, formed the Pooled Resource Open-Access 
ALS Clinical Trials (PRO-ACT) Consortium. The data available in the PRO-ACT Database has been 
volunteered by PRO-ACT Consortium members. We then used the permutation test to examine whether 
there was heterogeneity in individual treatment effects. Pro-ACT includes information from more than 
8,500 patients with ALS, each of them participated in a clinical trial and received either a placebo or an 
experimental treatment. Following Küffner et al,35 we used the slope of the ALSFRS score from a 
repeated measures model for each patient as the primary outcome, and  the 2,910 patients (1,766 in 
experimental treatments and 1,144 in control ones) who had complete data for 17 covariates, treatment 
condition, and the outcome. 
 
To avoid overfitting the data we advocate either choosing both the predictive method to be used and the 
covariates for the PITEs a priori, or adjusting for the variable selection process.36 Here, we demonstrate 
the permutation test on the basis of a linear model that included 7 (out of 17) covariates that were found to 
have significant interaction treatment. Note that in its simplest form, with a linear model, PITE captures 
baseline by treatment interactions, thus we used this as the criteria for variable selection. PITEs, however, 
are much more general than these interactions as they capture the joint effect of many predictors and, 
depending on the predictive method used, implicitly capture non-linear and higher order interactions. The 
seven covariates used for obtaining PITE estimates were: respiratory rate, systolic blood pressure, age, 
gender, onset location in the Limb, use of Riluzole, and Delta Flag (coded 1 if the time between patient 
previously used Riluzole for than a year).  
Results 
Their descriptive statistics are shown in Appendix B and C. The linear regression model’s estimates for 
both treatment and control conditions, which are included in Appendix A, differ across conditions. These 
differences in estimates are what contribute to predicted individual differences in treatment effects. Figure 
1 includes the permutation distribution of SDs of PITEs based on the procedure outlined above together 
with the observed SD from the ALS dataset, which at .127 is on the upper tail of this distribution. The p-
value for the permutation test was .005, providing strong evidence for individual-level treatment 
heterogeneity.  
 
Figure 2. Permutation distribution of PITEs’ SDs and the observed PITE’s SD in the ALS study. 
 4. Type I error rates for the permutation test 
The promise of the permutation test is that one can use any conventional or machine learning function and 
still get correct frequency properties. In this section, we investigate if this promise is fulfilled. We begin 
our evaluation of the proposed test by examining the type I error rate of the proposed permutation test 
under the null hypothesis, i.e.,  that the treatment effect is the same for all individuals. Simulations were 
conducted with the true PITE for each individual being equal to the average treatment effect, meaning 
that covariates had no impact on the PITE, and that ?̂?𝑃𝐼𝑇𝐸  is what would be observed if the true value of 
𝜎𝑃𝐼𝑇𝐸  is chance. When the type I error is .05, the p-value obtained from step 7, above, should be 
uniformly distributed between 0 and 1 so that the p-value is below .05 in only 5% of the simulations. 
In this phase of our investigation, PITE was estimated with sample sizes of 100, 250, 500, 1,000, and 
5,000 using both linear regression (via the lm function in R) and Random Forests (via the 
randomForestSRC package in R,37 tuned to have a node depth of 10). To make the simulation more 
realistic, we included five prognostic covariates that had the same effects across the treatment and control 
conditions. These included three normally distributed covariates with means of 0 and variances of 1, and 
two binary variables, each with a 0.5 probability of endorsing 1 or 0. The covariate effects of 0.406, -
0.239, 0.703, -0.090, and -0.299 respectively were identical across the treatment and the control groups – 
implying that they did not predict differential responses to the treatment - and were included in all 
analyses. To show type I error rates when many additional variables were included in the predictive 
model, we ran analyses with varying numbers of continuous variables with standard normal distribution 
and binary variables with binomial distributions with a probability of success of .5. They were generated 
unrelated to the outcome, hereafter called ‘nuisance variables.’ Because sample size limits the number of 
nuisance variables that can be included in a linear regression model, we examined an increased number of 
nuisance variables with larger samples. Analyses also varied the true treatment effect, to show that the 
PITE as described above does not capture main effects of treatment. For the Random Forest model, we 
ran with 500 trees and used 10 random split points to split a node.  
 
Results 
 
The results of such analyses (see Table 1) established that across all conditions, the permutation test 
rejected the null hypothesis 4.7% to 6.3 % of the time with the linear regression model, and 2.9% to 6.3% 
of the time with Random Forests. The estimated type I errors appear to be mostly within simulation error 
(±0.007) with no discernable pattern to be detectable in relation to the number of nuisance variable, main 
effect or total sample size. 
 
5. Power of the permutation test  
Next, we used our ALS results as the basis for simulations examining some of the factors that influence 
the permutation test’s statistical power. In the data generation model for the power simulations, the 
parameters from the predictive linear model using the ALS example (shown in Appendix A) were used as 
the starting point. To mimic the real-world scenario, we included only the seven covariates that were 
found to have significant impacts on the PITE in the simulation. The first three of these, respiratory rate, 
systolic blood pressure, and age, were generated as normally distributed random variables with means and 
SDs equal to the corresponding values estimated from the ALS dataset (details of which are provided in 
Appendix B). Similarly, the remaining four binary random variables, gender, onset location in the limb, 
use of Riluzole, and Delta Flag, were generated as binomial with the same probabilities as observed (in 
Appendix C). The covariance matrix was generated by mimicking that of the ALS data. The outcome was 
generated with the effect size scaled to mimic the ALS example with sample sizes of 1,000 (to examine if 
the effects could have been found with a smaller sample) and 3,000 (as in the ALS example), with equal 
size for the treatment and placebo groups.  To assess the impact of adding further covariates when fitting 
PITE, we evaluated statistical power with 0, 20, 50 or 100 nuisance variables, all of which were generated 
either from standard normal distributions or from binomial distributions with a probability of success of 
.5. The nuisance variables were included when estimating PITEs despite not being related to the outcome.  
A challenge in estimating power was that measures of effect size for PITE have not been previously 
defined. In this study, we used the average PITE estimate divided by the pooled SD of the outcome as 
follows:  
𝑃𝐼𝑇𝐸 𝐸𝑓𝑓𝑒𝑐𝑡 𝑆𝑖𝑧𝑒 =
Σ|𝑃𝐼𝑇𝐸𝑖|
𝑁
√
(𝑁𝑇 − 1) × (σ𝑇
2 ) + (𝑁𝐶 − 1) × (𝜎𝐶
2)
𝑁𝑇 + 𝑁𝐶 − 1
  
This resulted in an estimated effect size of 0.19 for the PITEs in the ALS example, meaning that the 
average person was 0.19 SD from the average effect size. When estimating power, data were generated 
with effect sizes of either 0.19 or 0.38, with the latter included to examine the method’s ability to identify 
a larger effect.  
We also examined the permutation test’s power to detect heterogeneity that is mostly due to a single 
variable as well as when heterogeneity was spread across multiple variables which each contribute a small 
amount. Power simulations were run for six conditions, which differed from on another solely in terms of 
the relative contributes of the seven predictors. Specifically, these six conditions were: 1) the total 
heterogeneous effect is evenly spread across all seven covariates (“Spread”); 2) 90% of the total 
heterogeneous effect is due to the first continuous variable, and 10% to the other six covariates (“90/10 
Cont.”); 3) as 90/10 Cont., but with 75%/25% split between the first continuous variable and the other six 
covariates (“75/25 Cont.”); 4) as above, but with a 50%/50% split (“50/50 Cont.”);; 5) as above, but with 
a 25%/75% split (“25/75 Cont.”); 6) 90% of the total heterogeneous effect is due to the first binary 
variable, and 10% to the other six covariates (“90/10 Bin.”). Thus, the power of PITE prediction was 
examined in a total of 96 conditions, i.e., in 2 (sample sizes) × 4 (numbers of nuisance variables) × 2 
(effect sizes) × 6 (heterogeneity effect distributions). 
Once data was generated, both the linear model and Random Forests were run for each dataset and under 
each condition using the procedures described above. For the Random Forest model, the depth was 
restricted to 10. The percentage of times that the permutation test was significant for each condition 
recorded as the power estimate.  
Results  
Power for each of the 96 conditions was estimated as the proportion of 1000 simulations for which the 
permutation test was significant. The results obtained with an effect size of 0.19 are presented in Table 2, 
and those obtained with an effect size of 0.38 in Table 3. As expected, power increased both when sample 
size increased and when effect size increased. Our results also indicated that increasing the number of 
nuisance variables decreased power substantially, highlighting the importance of selecting meaningful 
covariates. With the ALS observed effect size and sample size, the predictive (post-hoc) power obtained 
from the linear regression model was adequate when there were 50 nuisance variables, but not when there 
were 100. When using Random Forests for predictions, on the other hand, power was adequate with 20 
nuisance variables at the same sample size. However, with a sample size of 1,000, the linear regression 
model’s power was poor even with 20 nuisance variables and would be inadequate with Random Forests 
using the same tuning parameters.  
With an effect size twice as great as observed, the power of the permutation test using linear 
regression model was low only when the sample size was 1,000 and there were 50 or 100 nuisance 
variables, but Random Forests’ power was marginal even with sample size of 3,000 if there were 100 
nuisance variables. That being said, we expected that the power estimates for Random Forests would 
generally be lower than those for the linear regression model, given that the data were simulated using the 
latter and that no higher order interactions or non-linear effects were included.  
The other factor that we varied across the simulations was how the effect of the covariates on 
heterogeneity in treatment effects was spread out. The reason for this is to show the core advantage of 
PITE, which is its ability to detect many small effects that add up to something meaningful rather than 
just one large effect. When looking across the six different spreads of the PITE effect, it was striking that 
when there was adequate power for one of them, there was usually adequate power for all. The only two 
exceptions to this were 1) when the effect was carried primarily by one binary variable (i.e., there are only 
two different kinds of responses), in which case, power was higher than for the other conditions; and 2) 
for random forests the power is lower for the binary predictor. The key result here is that, in the ALS 
example, power was about the same regardless of whether the heterogeneity in treatment effects is 
attributed primarily to one of the seven important variables or when it is spread out across all seven.  
One apparently inconsistent finding in these results was that in some condition, power was less 
than 5%, the type I error rate. The reason for this is that any random variable will cause variability in the 
PITE to a certain extent. In some cases, with many nuisance variables, the effects of the predictors we 
were simulating were smaller than effects due to chance, resulting in a lower probability of finding 
heterogeneity in the effects of the predictor than would have been expected due to chance. Importantly, 
this implies that adding more predictors will increase the noise in PITE estimates and result in larger 
heterogeneity being estimated.  
6. Discussion 
If PITEs are to be useful for quantifying individual differences in the effects of an intervention, it 
is necessary to have a test that can show that differences observed are not simply due to chance. The 
proposed permutation test is therefore a crucial step toward rendering this approach practical. Under the 
96 conditions we examined, the test was shown to have appropriate nominal type I error rates, practical 
utility in an applied example, and adequate power in that example given a moderately sized sample and 
20 to 50 covariates. We acknowledge that the effect size observed in our applied example was fairly small 
(the average individual was 0.19 SD from the average treatment effect). However, if the sample size had 
been doubled, then the permutation test would have had adequate power even with 100 nuisance 
covariates. The permutation test also demonstrated an ability to detect heterogeneity in treatment effects 
when that is due primarily to a single predictor, or when it was spread across the seven predictors that had 
an impact in the ALS example. It also worked reasonably well when either the linear regression model or 
Random Forests were used as the predictive method. This is important because a desirable property of the 
permutation test is that it is a non-parametric approach which can be applied with any predictive method 
and makes no assumptions beyond those of the method is being used to obtain PITEs. 
The permutation test was also found to have unexpected benefit, in that the variance of the PITE 
across permuted datasets provides an estimate of variability in PITE that, due to chance, can be attributed 
to unique conditions of a given application: e.g., the number and distribution of the covariates used, or the 
model or algorithm used to obtain predictions. Thus, this test can help assess the amount of noise added to 
the PITEs at a given number of covariates and a given predictive method.  
We noted that for Random Forests with nuisance variables the choice of tuning parameters made 
a meaningful difference in the results. If there is heterogeneity in treatment effects, or added nuisance 
variables, the Random Forest requires more tuning or would require to be corrected for bias, irrespective 
of sample size.  For instance, allowing deep trees led to high levels of overfitting, with many nuisance 
variables being identified as important. In that case, we chose a maximum node depth of 10 to reduce 
overfitting. However, questions of how to appropriately tune random forests when estimating PITEs are 
beyond the scope of this study. We mention this issue only to highlight that it is non-trivial in studies with 
many covariates which, while chosen because the researchers expect them to be important, may in fact be 
unrelated to heterogeneity in treatment effect. 
The limitations of this study are that we examined the proposed PITE permutation test using 
predictions from only the linear regression model and Random Forests (with one set of tuning 
parameters), and under a set of conditions that was designed to clarify our understanding of its power via 
an applied example. In principle, we see no reason why this test should not work well with any method 
chosen but cannot claim that the present paper has established this firmly. We should also note that, in the 
ALS example, the permutation test required a quite large sample to attain adequate power. While the 
observed effect size was small in this case, even with a larger effect, the test required an N of 3,000 if 
many covariates were included. Because the outcome of interest is individual predictions, we believe that 
PITEs will generally require substantial sample sizes, unless the target effects are very large. 
Nevertheless, as a new approach to testing the significant of heterogeneity, the test is likely to be of 
considerable benefit to other similar approaches in precision medicine.  
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Table 1. Type 1 error rates for the PITE permutation test, the linear regression model and Random 
Forests. 
Sample 
Size 
Number of 
Nuisance 
Continuous 
Covariates 
Number of 
Nuisance 
Binary 
Covariates 
Average 
Treatment 
Effects 
Upper-sided 
Type I Error 
Rate- LM 
Upper-sided 
Type I Error 
Rate- RF 
100 0 0 0 0.049 0.046 
100 0 0 0.5 0.047 0.029 
250 0 0 0 0.047 0.053 
250 75 35 0 0.052 0.060 
250 0 0 0.5 0.063 0.054 
250 75 35 0.5 0.061 0.030 
500 0 0 0 0.048 0.053 
500 75 35 0 0.056 0.047 
500 150 70 0 0.052 0.048 
500 0 0 0.5 0.053 0.051 
500 75 35 0.5 0.054 0.035 
500 150 70 0.5 0.050 0.047 
1000 0 0 0 0.043 0.051 
1000 75 35 0 0.043 0.046 
1000 150 70 0 0.053 0.039 
1000 0 0 0.5 0.050 0.038 
1000 70 35 0.5 0.046 0.042 
1000 150 70 0.5 0.062 0.041 
 
 
  
Table 2. Power to detect heterogeneity in treatment effects, based on the linear regression model and the 
Random Forest predictions from the ALS example with an effect size of 0.19 
Model 
Prediction 
Sample 
Size 
Number of 
Nuisance 
Variables 
Effect Distribution 
Spread 
90/10 
Cont. 
75/25 
Cont. 
50/50 
Cont. 
25/75 
Cont. 
90/10 
Bin. 
Linear 
Regression  
3,000 
0 1 1 1 1 1 1 
20 1 1 1 1 1 0.958 
50 0.924 1 0.998 0.968 0.988 0.878 
100 0.256 0.002 0.002 0.002 0.498 0.658 
1,000 
0 0.908 1 1 1 0.996 0.648 
20 0.294 0.062 0.058 0.098 0.496 0.392 
50 0.008 0 0 0 0.006 0.182 
100 0 0 0 0 0 0.112 
Random 
Forest  
3,000 
0  0.96 1 1 0.97 1 0.99 
20 0.94 0.91 0.91 0.90 0.97 0.91 
50 0.46 0.28 0.32 0.29 0.47 0.26 
100 0.01 0.00 0.00 0.02 0.01 0.00 
1,000 
0 0.23 0.08 0.06    0.10    0.44     0.42 
20 0.16 0.03 0.06 0.09 0.19 0.12 
50 0 0 0 0 0 0 
100  0 0 0 0 0 0 
 
Table 3. Power to detect heterogeneity in treatment effects, based on the linear regression model and the  
Random Forests predictions from the ALS example with an effect size of 0.38 
Model 
Prediction 
Sample 
Size 
Number 
of 
Nuisance 
Variables 
Effect Distribution 
Spread 
90/10 
Cont. 
75/25 
Cont. 
50/50 
Cont. 
25/75 
Cont. 
90/10 
Bin. 
Linear 
Regression  
3,000 
0 1 1 1 1 1 1 
20 1 1 1 1 1 1 
50 1 1 1 1 1 1 
100 1 1 1 1 1 1 
1,000 
0 1 1 1 1 1 1 
20 1 1 1 1 1 0.996 
50 0.682 0.106 0.108 0.158 0.582 0.944 
100 0 0 0 0 0 0.706 
Random 
Forest  
3,000 
0 1 1 1 1 1 1 
20 1 1 1 1 1 1 
50 1 1 1 1 1 1 
100 0.81 0.60 0.55 0.52 0.66 0.74 
1,000 
0 1 1 1 1 1 0.99 
20 0.97 0.94 0.98 0.98 0.99 0.99 
50 0.29 0.18 0.11 0.16 0.24 0.24 
100 0 0 0 0 0 0 
  
APPENDIX 
A. Parameter estimates from the linear regression model using the ALS example with 17 selected 
covariates. 
Covariates 
Coefficients of the 
Treatment Group  
Coefficients of the 
Control Group  
(Intercept) -3.56945 -2.88826 
Delta Flag 0.01969 0.17810 
Respiratory Rate -0.00099 0.01067 
Temperature 0.10752 0.09247 
Weight(kg) 0.00226 0.00166 
Height(cm) -0.00555 -0.00442 
Diastolic Blood Pressure -0.00311 -0.00204 
Systolic Blood Pressure 0.00110 -0.00113 
Pulse -0.00365 -0.00431 
Gender 0.00712 -0.03439 
Age 0.00130 -0.00327 
White 0.03524 -0.01493 
severity -0.04591 -0.06893 
Diagnosis Delta -0.00036 -0.00022 
Limb Only -0.08336 0.08838 
Bulbar Only -0.33667 -0.08348 
Start Delta -0.00019 -0.00037 
Use Riluzole -0.07150 -0.22549 
 
B. Means and SDs of the continuous covariates in the ALS example 
 Mean SD Median Min. Max. 
Systolic Blood Pressure 131.88 16.63 130 85 206 
Age 54.70 11.35 55 18 80 
Respiratory Rate 17.19 3.27 16 6 42 
 
C. Distribution of binary covariates in the ALS example 
 Category N Percentage 
Delta Flag (longer than 1 year) Yes 93 3.20% 
 No 2817 96.80% 
Limb Only Yes 1952 67.08% 
 No 958 32.92% 
Gender Male 1848 63.51% 
 Female 1062 36.49% 
Use Riluzole Yes 1112 38.21% 
 No 1798 61.79% 
 
